3.85
+0.17(+4.62%)
Currency In USD
Address
2440 Research Boulevard
Rockville, MD 20850
United States of America
Phone
240 745 6330
Sector
Healthcare
Industry
Biotechnology
Employees
32
First IPO Date
January 17, 2020
| Name | Title | Pay | Year Born |
| Dr. Xi-Yong Fu M.B.A., Ph.D. | Chief Executive Officer & Director | 0 | 1972 |
| Mr. Sean Wuxiong Cao M.B.A., Ph.D. | Chief Business Development Officer & Independent Director | 0 | N/A |
| Mr. Wei Fu | Executive Chairman | 0 | 1982 |
| Mr. Tyler Ehler | Senior Director of Investor Relations | 0 | N/A |
| Kyler Lei | Chief Financial Officer | 0 | N/A |
| Dr. Phillip Dennis M.D., Ph.D. | Chief Medical Officer | 0 | 1963 |
| Dr. Claire Xu M.D., Ph.D. | Senior Vice President of Clinical Development | 0 | N/A |
NovaBridge Biosciences, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell, and offer to sell FE301, an interleukin-6 inhibitor. The company also has collaborations with Bristol Myers Squibb for the development of givastomig; ABL Bio, Inc. for the development of givastomig and ragistomig; and TJ Bio for the development of uliledlimab. The company was formerly known as I-Mab and change its name to NovaBridge Biosciences in October 2025. NovaBridge Biosciences was founded in 2014 and is headquartered in Rockville, Maryland.